首页 > 最新文献

Antibiotics and Chemotherapy最新文献

英文 中文
Probiotics and Autoprobiotics in the Treatment of Experimental Vaginitis 益生菌与自体益生菌治疗实验性阴道炎
Pub Date : 2023-02-11 DOI: 10.37489/0235-2990-2022-67-11-12-29-35
E. Ermolenko, O. E. Punchenko, L. Voropaeva, A. V. Swarwal, M. Kotyleva, A. Suvorov
The wide prevalence of inflammatory vaginal diseases in women of different ages, a significant deterioration in the quality of life due to their presence, as well as an adverse effect on conception and the course of pregnancy make the search for more efficient and safe therapy of vaginitis an urgent issue. The article presents the results of experimental staphylococcal vaginitis treatment with probiotics and autoprobiotics in rat models, including hormonized animals after ovariectomy. The effectiveness of topical application of the probiotic strain E. faecium L3 in rats has been confirmed. The probiotic proved to be effective both in rats with a hormonized cycle and in rats with preserved ovaries. Among the tested autoprobiotic and homologous (rat) strains, the elimination of staphylococci occurred faster after the introduction of bifidobacterial. However, lactobacilli are more reliable in protection against the recurrence of infection. At the same time, homologous strains of both lactobacilli and bifidobacteria contribute to faster elimination of the pathogen compared to autostamps.
阴道炎在不同年龄的妇女中广泛流行,生活质量因其存在而显著下降,对受孕和妊娠过程产生不利影响,因此寻找更有效和安全的阴道炎治疗方法是一个紧迫的问题。本文介绍了用益生菌和自身益生菌治疗葡萄球菌性阴道炎的实验结果,包括卵巢切除术后的激素化动物。益生菌菌株粪肠杆菌L3在大鼠局部应用的有效性已被证实。事实证明,益生菌对激素周期的大鼠和保留卵巢的大鼠都有效。在所测试的自体益生菌和同源(大鼠)菌株中,引入双歧杆菌后葡萄球菌的消除速度更快。然而,乳酸菌在防止感染复发方面更可靠。与此同时,乳酸菌和双歧杆菌的同源菌株与自动印记相比,有助于更快地消除病原体。
{"title":"Probiotics and Autoprobiotics in the Treatment of Experimental Vaginitis","authors":"E. Ermolenko, O. E. Punchenko, L. Voropaeva, A. V. Swarwal, M. Kotyleva, A. Suvorov","doi":"10.37489/0235-2990-2022-67-11-12-29-35","DOIUrl":"https://doi.org/10.37489/0235-2990-2022-67-11-12-29-35","url":null,"abstract":"The wide prevalence of inflammatory vaginal diseases in women of different ages, a significant deterioration in the quality of life due to their presence, as well as an adverse effect on conception and the course of pregnancy make the search for more efficient and safe therapy of vaginitis an urgent issue. The article presents the results of experimental staphylococcal vaginitis treatment with probiotics and autoprobiotics in rat models, including hormonized animals after ovariectomy. The effectiveness of topical application of the probiotic strain E. faecium L3 in rats has been confirmed. The probiotic proved to be effective both in rats with a hormonized cycle and in rats with preserved ovaries. Among the tested autoprobiotic and homologous (rat) strains, the elimination of staphylococci occurred faster after the introduction of bifidobacterial. However, lactobacilli are more reliable in protection against the recurrence of infection. At the same time, homologous strains of both lactobacilli and bifidobacteria contribute to faster elimination of the pathogen compared to autostamps.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81654453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is There a Need to Widely Prescribe Antibiotics in Patients with COVID-19? 是否有必要在COVID-19患者中广泛开抗生素?
Pub Date : 2023-02-10 DOI: 10.37489/0235-2990-2022-67-11-12-64-78
N. Karoli, A. Rebrov
Over the past two years, the SARS-CoV-2 pandemic has dominated all aspects of health care around the world, often leaving other long-term public health problems in the background. Despite the fact that COVID-19 is a viral disease, the use of antibiotics in these patients was common practice, especially at the beginning of the pandemic. The use of antibiotics (ABs) in patients with the novel coronavirus infection (NCI) reaches over 70% cases. Suspected concomitant bacterial infection, lack of effective means of treating NCI, terminological problems associated with the definition of «pneumonia» may have been the motivating factor for such widespread use. The data of the conducted studies indicate that there is currently insufficient evidence for the widespread empirical use of antibiotics in the majority of hospitalized patients, as the total proportion of bacterial infections in COVID-19 is quite low. Thus, according to most researchers, combined bacterial infection is rare and is less than 10%. Unjustified prescription of ABs to patients with COVID-19 can lead to complications that could otherwise have been avoided, including increased bacterial resistance, Clostridioides difficile infection, kidney failure, and much more. The article provides information on the frequency of AB therapy at various stages of medical care. The analysis of data on the nature of antibiotics prescribed to inpatients and outpatients with COVID-19 in different countries was carried out. Recommendations from different countries on AB therapy in patients with COVID-19 are presented. Conclusion. The data reviewed confirm the discrepancy between the unjustified and excessive prescribing of antibiotics to patients with COVID-19 and the small number of evidence of associated bacterial infections.
在过去两年中,SARS-CoV-2大流行主导了全球卫生保健的各个方面,往往将其他长期公共卫生问题置于次要地位。尽管COVID-19是一种病毒性疾病,但在这些患者中使用抗生素是一种常见做法,特别是在大流行开始时。新型冠状病毒感染(NCI)患者使用抗生素(ABs)的病例达到70%以上。疑似伴随细菌感染、缺乏治疗非传染性疾病的有效手段、与“肺炎”定义相关的术语问题可能是这种广泛使用的激励因素。所开展的研究数据表明,由于COVID-19中细菌感染的总比例很低,目前大多数住院患者普遍经验性使用抗生素的证据不足。因此,根据大多数研究人员的说法,合并细菌感染是罕见的,不到10%。给COVID-19患者开具不合理的抗体处方可能导致原本可以避免的并发症,包括细菌耐药性增强、艰难梭菌感染、肾衰竭等等。这篇文章提供了在医疗护理的不同阶段AB治疗频率的信息。对不同国家COVID-19住院和门诊患者使用抗生素的性质进行数据分析。介绍了不同国家对COVID-19患者AB治疗的建议。结论。审查的数据证实,对COVID-19患者不合理和过度开具抗生素处方与少量相关细菌感染证据之间存在差异。
{"title":"Is There a Need to Widely Prescribe Antibiotics in Patients with COVID-19?","authors":"N. Karoli, A. Rebrov","doi":"10.37489/0235-2990-2022-67-11-12-64-78","DOIUrl":"https://doi.org/10.37489/0235-2990-2022-67-11-12-64-78","url":null,"abstract":"Over the past two years, the SARS-CoV-2 pandemic has dominated all aspects of health care around the world, often leaving other long-term public health problems in the background. Despite the fact that COVID-19 is a viral disease, the use of antibiotics in these patients was common practice, especially at the beginning of the pandemic. The use of antibiotics (ABs) in patients with the novel coronavirus infection (NCI) reaches over 70% cases. Suspected concomitant bacterial infection, lack of effective means of treating NCI, terminological problems associated with the definition of «pneumonia» may have been the motivating factor for such widespread use. The data of the conducted studies indicate that there is currently insufficient evidence for the widespread empirical use of antibiotics in the majority of hospitalized patients, as the total proportion of bacterial infections in COVID-19 is quite low. Thus, according to most researchers, combined bacterial infection is rare and is less than 10%. Unjustified prescription of ABs to patients with COVID-19 can lead to complications that could otherwise have been avoided, including increased bacterial resistance, Clostridioides difficile infection, kidney failure, and much more. The article provides information on the frequency of AB therapy at various stages of medical care. The analysis of data on the nature of antibiotics prescribed to inpatients and outpatients with COVID-19 in different countries was carried out. Recommendations from different countries on AB therapy in patients with COVID-19 are presented. Conclusion. The data reviewed confirm the discrepancy between the unjustified and excessive prescribing of antibiotics to patients with COVID-19 and the small number of evidence of associated bacterial infections.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87671675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Issue of Post-COVID Syndrome in Children and Adolescents: Approaches to Terminology, Pathogenesis, Clinical Manifestations, Diagnosis, and Treatment 儿童和青少年covid - 19后综合征问题:术语、发病机制、临床表现、诊断和治疗方法
Pub Date : 2023-02-10 DOI: 10.37489/0235-2990-2022-67-11-12-51-55
E. N. Serebryakova, L. I. Zhmaeva
The article discusses the issues of terminology, epidemiology, etiopathogenesis, clinical manifestations, approaches to the diagnosis and treatment of post-covid syndrome (PCS). It has been shown that the incidence of PCS in people who had COVID-19 is 10–35%; there are no generally accepted approaches to defining the term PCS. Clinical manifestations of PCS include more than 50 symptoms that occur in both children and adults, regardless of their place of residence. The damage caused by metabolites of the systemic inflammatory response of the central nervous system with the formation of a syndrome of autonomic dysfunction,  cognitive  impairment,  and affective disorders is of critical importance  in the genesis of PCS.  Antipsychotics, antidepressants, and benzodiazepine drugs are used in the correction of PCS. However, they have limitations, in particular — when used in children with comorbid disorders. The use of aminoacetic acid (glycine), which has a wide range of safety,anxiolytic, anti-inflammatory, and nootropic effects in the correction of PCS, can become an effective therapeutic strategy.
本文就新冠肺炎后综合征的术语、流行病学、发病机制、临床表现、诊断和治疗方法等问题进行了探讨。有研究表明,COVID-19患者中PCS的发病率为10-35%;目前还没有普遍接受的方法来定义PCS这个术语。PCS的临床表现包括50多种儿童和成人均可出现的症状,无论其居住在何处。中枢神经系统全身性炎症反应的代谢物引起的损伤,形成自主神经功能障碍、认知障碍和情感障碍综合征,在PCS的发生中起着至关重要的作用。抗精神病药、抗抑郁药和苯二氮卓类药物用于矫正PCS。然而,它们有局限性,特别是在用于患有合并症的儿童时。氨基乙酸(甘氨酸)具有广泛的安全性、抗焦虑性、抗炎性和促智性作用,可以成为一种有效的治疗策略。
{"title":"The Issue of Post-COVID Syndrome in Children and Adolescents: Approaches to Terminology, Pathogenesis, Clinical Manifestations, Diagnosis, and Treatment","authors":"E. N. Serebryakova, L. I. Zhmaeva","doi":"10.37489/0235-2990-2022-67-11-12-51-55","DOIUrl":"https://doi.org/10.37489/0235-2990-2022-67-11-12-51-55","url":null,"abstract":"The article discusses the issues of terminology, epidemiology, etiopathogenesis, clinical manifestations, approaches to the diagnosis and treatment of post-covid syndrome (PCS). It has been shown that the incidence of PCS in people who had COVID-19 is 10–35%; there are no generally accepted approaches to defining the term PCS. Clinical manifestations of PCS include more than 50 symptoms that occur in both children and adults, regardless of their place of residence. The damage caused by metabolites of the systemic inflammatory response of the central nervous system with the formation of a syndrome of autonomic dysfunction,  cognitive  impairment,  and affective disorders is of critical importance  in the genesis of PCS.  Antipsychotics, antidepressants, and benzodiazepine drugs are used in the correction of PCS. However, they have limitations, in particular — when used in children with comorbid disorders. The use of aminoacetic acid (glycine), which has a wide range of safety,anxiolytic, anti-inflammatory, and nootropic effects in the correction of PCS, can become an effective therapeutic strategy.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84272021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ototoxicity of Aminoglycosides the Modern Concepts 氨基糖苷类耳毒性的现代概念
Pub Date : 2023-02-09 DOI: 10.37489/0235-2990-2022-67-11-12-79-90
E. V. Shubnikova, N. Y. Velts
Aminoglycosides are broad-spectrum antibacterial agents used  in the treatment of urinary  tract infections, tuberculosis, visceral leishmaniasis, sepsis in newborns, as well as cystic fibrosis. However, the use of aminoglycosides is limited due to their ototoxicity — the risk of developing serious adverse  reactions, in particular, persistent irreversible hearing loss and vestibular disorders associated with the death of hair cells in the inner ear. The review analyzes scientific data on the possible mechanisms of aminoglycosides’ damaging effect  on the hair cells  of the inner  ear. Genetically determined causes contributing to the manifestation of ototoxic properties of drugs of this group are described. The necessity of genetic screening for the carriage  of mutations m.1555A>G  and m.1494C>T in the MT-RNR1 gene  of mitochondrial DNA is substantiated in order to minimize the risk of hearing disorders in patients with hereditary predisposition. Understanding the mechanisms of ototoxicity of aminoglycosides will make it possible to find ways to prevent and correct hearing loss after their use.
氨基糖苷类是广谱抗菌剂,用于治疗尿路感染、结核病、内脏利什曼病、新生儿败血症以及囊性纤维化。然而,氨基糖苷类药物的使用受到限制,因为它们具有耳毒性——有发生严重不良反应的风险,特别是与内耳毛细胞死亡相关的持续不可逆的听力损失和前庭功能障碍。本文分析了氨基糖苷类物质对内耳毛细胞损伤的可能机制。遗传决定的原因有助于这组药物的耳毒性的表现被描述。证实了对线粒体DNA MT-RNR1基因携带m.1555A>G和m.1494C>T突变进行遗传筛查的必要性,以降低遗传易感性患者发生听力障碍的风险。了解氨基糖苷类药物的耳毒性机制,有助于找到预防和纠正其使用后听力损失的方法。
{"title":"Ototoxicity of Aminoglycosides the Modern Concepts","authors":"E. V. Shubnikova, N. Y. Velts","doi":"10.37489/0235-2990-2022-67-11-12-79-90","DOIUrl":"https://doi.org/10.37489/0235-2990-2022-67-11-12-79-90","url":null,"abstract":"Aminoglycosides are broad-spectrum antibacterial agents used  in the treatment of urinary  tract infections, tuberculosis, visceral leishmaniasis, sepsis in newborns, as well as cystic fibrosis. However, the use of aminoglycosides is limited due to their ototoxicity — the risk of developing serious adverse  reactions, in particular, persistent irreversible hearing loss and vestibular disorders associated with the death of hair cells in the inner ear. The review analyzes scientific data on the possible mechanisms of aminoglycosides’ damaging effect  on the hair cells  of the inner  ear. Genetically determined causes contributing to the manifestation of ototoxic properties of drugs of this group are described. The necessity of genetic screening for the carriage  of mutations m.1555A>G  and m.1494C>T in the MT-RNR1 gene  of mitochondrial DNA is substantiated in order to minimize the risk of hearing disorders in patients with hereditary predisposition. Understanding the mechanisms of ototoxicity of aminoglycosides will make it possible to find ways to prevent and correct hearing loss after their use.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89503274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Antimicrobial Therapy and COVID-19 — the 'Great Confrontation' 抗菌药物治疗与COVID-19——“大对抗”
Pub Date : 2022-12-29 DOI: 10.37489/0235-2990-2022-67-9-10-63-68
A. Zaytsev, A. Makarevich
The problem of antimicrobial therapy (AMT) for the new coronavirus infection has been the cornerstone of practical healthcare since its emergence to the present day. The article summarizes a number of problems concerning the unjustified prescription of AMT based on the data of foreign and domestic studies, as well as actual clinical practice. On the one hand, viral damage to the lung tissue during COVID-19 is difficult to distinguish from community-acquired or secondary bacterial pneumonia; it prompts clinicians to prevent possible bacterial complications in the lungs by prescribing broad-spectrum antibiotics starting from the first day. On the other hand, the presence of clear clinical and biological markers of bacterial pneumonia; and COVID-19 makes it possible not to use antibiotics in routine practice, at least in the early stages of treatment. The introduction of procalcitonin as a biomarker of bacterial infection in COVID-19 into everyday clinical practice has a reasonable, methodical, and scientific approach to prescribing antibiotics.
新型冠状病毒感染的抗菌治疗(AMT)问题自出现至今一直是实际医疗保健的基石。本文结合国内外研究数据,结合临床实际,总结了AMT处方不合理的若干问题。一方面,COVID-19期间肺组织的病毒损伤与社区获得性或继发性细菌性肺炎难以区分;它提示临床医生从第一天开始就开广谱抗生素来预防肺部可能出现的细菌并发症。另一方面,是否存在明确的细菌性肺炎临床和生物学标志物;COVID-19使得在常规实践中不使用抗生素成为可能,至少在治疗的早期阶段是这样。将降钙素原作为COVID-19细菌感染的生物标志物引入日常临床实践,是合理、系统和科学的抗生素处方方法。
{"title":"Antimicrobial Therapy and COVID-19 — the 'Great Confrontation'","authors":"A. Zaytsev, A. Makarevich","doi":"10.37489/0235-2990-2022-67-9-10-63-68","DOIUrl":"https://doi.org/10.37489/0235-2990-2022-67-9-10-63-68","url":null,"abstract":"The problem of antimicrobial therapy (AMT) for the new coronavirus infection has been the cornerstone of practical healthcare since its emergence to the present day. The article summarizes a number of problems concerning the unjustified prescription of AMT based on the data of foreign and domestic studies, as well as actual clinical practice. On the one hand, viral damage to the lung tissue during COVID-19 is difficult to distinguish from community-acquired or secondary bacterial pneumonia; it prompts clinicians to prevent possible bacterial complications in the lungs by prescribing broad-spectrum antibiotics starting from the first day. On the other hand, the presence of clear clinical and biological markers of bacterial pneumonia; and COVID-19 makes it possible not to use antibiotics in routine practice, at least in the early stages of treatment. The introduction of procalcitonin as a biomarker of bacterial infection in COVID-19 into everyday clinical practice has a reasonable, methodical, and scientific approach to prescribing antibiotics.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75887451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Pneumocystis Pneumonia in Rheumatic Diseases: Prevention Issues 风湿疾病中的肺囊虫肺炎:预防问题
Pub Date : 2022-12-29 DOI: 10.37489/0235-2990-2022-67-9-10-79-89
G. Gridneva, B. Belov, E. Aronova
The incidence of pneumocystis pneumonia (PCP) in patients with rheumatic diseases (RD) continues to increase. This is facilitated by the increasing use of genetically engineered biological agents in addition to the use of cytostatics and glucocorticoids. Mortality due to PCP among patients with RD is extremely high, so the issues of its prevention are relevant. European and American scientists focus on the frequency of detection of PCP and the determination of the proportionality of certain risk factors, while the recommendations for prevention are formulated cautiously. Asian medical communities are unanimous in their opinion about the need to prevent PCP, only the dosage of drugs and the duration of the course of treatment are discussed.
风湿病(RD)患者肺囊虫性肺炎(PCP)的发病率持续上升。除了使用细胞抑制剂和糖皮质激素外,越来越多地使用基因工程生物制剂也促进了这一点。由于PCP在RD患者中的死亡率非常高,因此其预防问题是相关的。欧美科学家关注的是PCP的检测频率和确定某些危险因素的比例,而预防建议则是谨慎制定的。亚洲医学界对预防PCP的意见是一致的,只是对药物的剂量和疗程的长短进行了讨论。
{"title":"Pneumocystis Pneumonia in Rheumatic Diseases: Prevention Issues","authors":"G. Gridneva, B. Belov, E. Aronova","doi":"10.37489/0235-2990-2022-67-9-10-79-89","DOIUrl":"https://doi.org/10.37489/0235-2990-2022-67-9-10-79-89","url":null,"abstract":"The incidence of pneumocystis pneumonia (PCP) in patients with rheumatic diseases (RD) continues to increase. This is facilitated by the increasing use of genetically engineered biological agents in addition to the use of cytostatics and glucocorticoids. Mortality due to PCP among patients with RD is extremely high, so the issues of its prevention are relevant. European and American scientists focus on the frequency of detection of PCP and the determination of the proportionality of certain risk factors, while the recommendations for prevention are formulated cautiously. Asian medical communities are unanimous in their opinion about the need to prevent PCP, only the dosage of drugs and the duration of the course of treatment are discussed.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":"52 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76656856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current State of the Streptococcus pneumoniae Capsular Typing Problem 肺炎链球菌荚膜分型问题的现状
Pub Date : 2022-12-29 DOI: 10.37489/0235-2990-2022-67-9-10-69-78
Y. Zakharova, V. Akimkin, E. V. Nikitina, I. A. Ivashchenko, E. Bolgarova, E. V. Aleksandrova, S. M. Skripkovskaya
Diseases caused by Streptococcus pneumoniae are a serious medical and social problem for healthcare systems of all leading countries around the globe. In this regard, the relevance of their laboratory diagnostics increases, as the effectiveness of therapeutic, preventive, and anti-epidemic measures depends on it. Currently, there is no universal method of intraspecific identification of S.pneumoniae, which simultaneously possess high specificity, sensitivity, and reproducibility. For this purpose, new alternative strategies aimed at improving the quality of research are being developed. The review presents data from domestic and foreign publications (electronic search databases eLibrary.Ru, ScienceDirect, Scopus, PubMed, Springerlink) on serotyping and genotyping of S.pneumoniae; the advantages and disadvantages of the methods are analyzed. Epidemiologically significant serotypes and widespread clonal complexes of S.pneumoniae circulating on the territory of the Russian Federation have been identified. The necessity of improving new methods of intraspecific typing of the pathogen is recognized.
肺炎链球菌引起的疾病是全球所有主要国家卫生保健系统面临的严重医疗和社会问题。在这方面,实验室诊断的相关性增加了,因为治疗、预防和反流行病措施的有效性取决于它。目前尚没有一种通用的肺炎链球菌种内鉴定方法,该方法同时具有较高的特异性、敏感性和可重复性。为此目的,正在制订旨在提高研究质量的新的备选战略。本文介绍了国内外文献资料(电子检索数据库)。Ru, ScienceDirect, Scopus, PubMed, Springerlink)对肺炎链球菌血清分型和基因分型的研究;分析了各种方法的优缺点。已确定在俄罗斯联邦境内流行的肺炎链球菌具有流行病学意义的血清型和广泛存在的克隆复合体。认识到改进病原体种内分型新方法的必要性。
{"title":"Current State of the Streptococcus pneumoniae Capsular Typing Problem","authors":"Y. Zakharova, V. Akimkin, E. V. Nikitina, I. A. Ivashchenko, E. Bolgarova, E. V. Aleksandrova, S. M. Skripkovskaya","doi":"10.37489/0235-2990-2022-67-9-10-69-78","DOIUrl":"https://doi.org/10.37489/0235-2990-2022-67-9-10-69-78","url":null,"abstract":"Diseases caused by Streptococcus pneumoniae are a serious medical and social problem for healthcare systems of all leading countries around the globe. In this regard, the relevance of their laboratory diagnostics increases, as the effectiveness of therapeutic, preventive, and anti-epidemic measures depends on it. Currently, there is no universal method of intraspecific identification of S.pneumoniae, which simultaneously possess high specificity, sensitivity, and reproducibility. For this purpose, new alternative strategies aimed at improving the quality of research are being developed. The review presents data from domestic and foreign publications (electronic search databases eLibrary.Ru, ScienceDirect, Scopus, PubMed, Springerlink) on serotyping and genotyping of S.pneumoniae; the advantages and disadvantages of the methods are analyzed. Epidemiologically significant serotypes and widespread clonal complexes of S.pneumoniae circulating on the territory of the Russian Federation have been identified. The necessity of improving new methods of intraspecific typing of the pathogen is recognized.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":"116 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86082094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study on Antiviral Activity and Pharmacological Safety of Double-Stranded Ribonucleic Acid for Intranasal Administration 鼻用双链核糖核酸抗病毒活性及药理安全性研究
Pub Date : 2022-12-28 DOI: 10.37489/0235-2990-2022-67-9-10-42-48
S. G. Gamaley, G. G. Shimina, E. S. Tsyplenkova, O. V. Simakova, M. Skarnovich, M. A. Skarnovich, L. Shishkina, O. Taranov, O. S. Ivanova, G. M. Levagina, E. Danilenko
Interferon inducers are of interest as the first line of defense against viral infections, including influenza. Double-stranded ribonucleic acid (dsRNA) for intranasal administration has been developed, the excipients and drug components were selected at the Institute of Medical Biotechnology, a branch of the State Research Center of Virology and Biotechnology «Vector». This work presents the results of the study on antiviral activity and pharmacological safety of a new form of dsRNA. The antiviral activity of the preparation was studied in BALB/c mice infected with influenza A/Aichi/2/68 (H3N2) or Bishkek/01/2009 (H1N1pdm09) viruses. A safety study was performed with a single administration of intranasal dsRNA into white outbred ICR mice. The study showed that the administration of therapeutic and prophylactic regimen of intranasal dsRNA at a dose of 2.5 mg/kg increases the survival and average life expectancy of mice infected with the mentioned strains of influenza virus. The protective effect of the preparation in mice infected with a lethal dose of Bishkek/01/2009 virus was comparable to the effect of Tamiflu. The absence of toxic effects of intranasal dsRNA at a pharmacological dose in laboratory mice, the functional state of their physiological systems, as well as main types of metabolism, established in the experiments, lead to a conclusion concerning pharmacological safety of the preparation and the prospects for further work to complete pharmaceutical development of a new antiviral drug.
干扰素诱导剂作为抵御病毒感染(包括流感)的第一道防线,引起了人们的兴趣。用于鼻内给药的双链核糖核酸(dsRNA)已经开发,赋形剂和药物成分是在国家病毒学和生物技术研究中心“载体”分支机构医学生物技术研究所选择的。本文介绍了一种新型dsRNA的抗病毒活性和药理安全性的研究结果。研究了该制剂对感染甲型流感病毒/爱知/2/68 (H3N2)和比什凯克/01/2009 (H1N1pdm09)的BALB/c小鼠的抗病毒活性。一项安全性研究通过单次给药鼻内dsRNA到白色杂交ICR小鼠。研究表明,治疗性和预防性的鼻内dsRNA剂量为2.5 mg/kg,可提高感染上述流感病毒株的小鼠的存活率和平均预期寿命。该制剂对感染致死剂量比什凯克/01/2009病毒的小鼠的保护作用与达菲的作用相当。实验小鼠鼻内dsRNA在药理学剂量下无毒性作用,实验确定了小鼠生理系统的功能状态以及主要代谢类型,得出了有关该制剂的药理学安全性的结论,并展望了进一步工作以完成新型抗病毒药物的药物开发。
{"title":"Study on Antiviral Activity and Pharmacological Safety of Double-Stranded Ribonucleic Acid for Intranasal Administration","authors":"S. G. Gamaley, G. G. Shimina, E. S. Tsyplenkova, O. V. Simakova, M. Skarnovich, M. A. Skarnovich, L. Shishkina, O. Taranov, O. S. Ivanova, G. M. Levagina, E. Danilenko","doi":"10.37489/0235-2990-2022-67-9-10-42-48","DOIUrl":"https://doi.org/10.37489/0235-2990-2022-67-9-10-42-48","url":null,"abstract":"Interferon inducers are of interest as the first line of defense against viral infections, including influenza. Double-stranded ribonucleic acid (dsRNA) for intranasal administration has been developed, the excipients and drug components were selected at the Institute of Medical Biotechnology, a branch of the State Research Center of Virology and Biotechnology «Vector». This work presents the results of the study on antiviral activity and pharmacological safety of a new form of dsRNA. The antiviral activity of the preparation was studied in BALB/c mice infected with influenza A/Aichi/2/68 (H3N2) or Bishkek/01/2009 (H1N1pdm09) viruses. A safety study was performed with a single administration of intranasal dsRNA into white outbred ICR mice. The study showed that the administration of therapeutic and prophylactic regimen of intranasal dsRNA at a dose of 2.5 mg/kg increases the survival and average life expectancy of mice infected with the mentioned strains of influenza virus. The protective effect of the preparation in mice infected with a lethal dose of Bishkek/01/2009 virus was comparable to the effect of Tamiflu. The absence of toxic effects of intranasal dsRNA at a pharmacological dose in laboratory mice, the functional state of their physiological systems, as well as main types of metabolism, established in the experiments, lead to a conclusion concerning pharmacological safety of the preparation and the prospects for further work to complete pharmaceutical development of a new antiviral drug.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82122992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study of Transitional Dynamics Towards the Non-Culturable State of Antibiotic-Resistant Escherichia coli Cells 耐药大肠杆菌细胞向不可培养状态过渡动力学的研究
Pub Date : 2022-12-28 DOI: 10.37489/0235-2990-2022-67-9-10-11-17
Yu. D. Pakhomov, L. Blinkova, A. M. Abdullaeva, R. K. Valitova
Background. It is known that bacteria develop resistance to antibiotics in response to their presence and tend to maintain it for a long time. In addition, microbes can remain viable by passing into an uncultivated state that is not detected by microbiological methods. This state of the population is characterized by cell resistance to various stresses, including the effects of antibiotics.Aim. To study the parameters of transition into an uncultivated state in E.coli M-17 cells resistant to an antibiotic.Material and methods. Resistant E.coli M-17 cells were obtained by culturing the initial population in media with increasing concentrations of ampicillin (up to 50 µg/mL). Seed cultures were prepared from sensitive and resistant substrains, from which the cells were transferred to a hyperosmotic, «starvation» medium — artificial sea water. The resulting populations were incubated for a long time, samples were periodically taken to conduct the assessment of viability parameters.Results. The experiments on long-term incubation of sensitive and resistant populations of E.coli M-17 showed that ampicillin-resistant substrain of the studied culture transitioned into an uncultivated state significantly faster and quantitatively higher than its sensitive variant. The presence of the antibiotic in the inoculum increased the time for the transition of resistant R2 bacteria to a viable uncultivated state to a level of >90% compared to R1. The R1 population at the beginning of the stress exposure massively (up to 77.7%) transitioned into viable but non-culturable cells (VBNCs) in the medium without an antibiotic in a similar seed culture. Periods of cell death were noted during the observation, with those cells becoming a substrate for the living part of the population and could lead to secondary growth of bacteria or partial restoration of dormant cells.Conclusion. Cells resistant to the antibiotic quickly transitioned into the non-culturable state compared to sensitive cells of the studied strain. The addition of an antibiotic to the medium for obtaining a seed culture slowed down the transition of cells to an uncultivated state.
背景。众所周知,细菌对抗生素的存在产生耐药性,并倾向于维持很长时间。此外,微生物可以通过进入微生物学方法检测不到的未培养状态而保持活力。这种种群状态的特征是细胞对各种压力的抵抗力,包括抗生素的作用。研究耐药大肠杆菌M-17细胞向非培养状态转变的参数。材料和方法。在增加氨苄西林浓度(高达50µg/mL)的培养基中培养初始群体,获得耐药的大肠杆菌M-17细胞。从敏感和抗性菌株中制备种子培养物,将细胞转移到高渗的“饥饿”培养基-人工海水中。将得到的种群孵育较长时间,并定期取样进行活力参数评估。对大肠杆菌M-17敏感和耐药群体的长期孵育实验表明,所研究培养物的耐氨苄西林亚株比其敏感变异株转变为未培养状态的速度和数量显著增加。与R1相比,接种物中抗生素的存在增加了抗性R2细菌向有活力的未培养状态过渡的时间,达到> - 90%的水平。在类似的种子培养中,在没有抗生素的培养基中,应激暴露开始时R1群体大量(高达77.7%)转变为有活力但不可培养的细胞(vbnc)。在观察过程中注意到细胞死亡的时期,这些细胞成为种群中活着的部分的基质,并可能导致细菌的二次生长或休眠细胞的部分恢复。与研究菌株的敏感细胞相比,对抗生素耐药的细胞迅速转变为不可培养状态。在获得种子培养的培养基中添加抗生素可以减缓细胞向未培养状态的转变。
{"title":"Study of Transitional Dynamics Towards the Non-Culturable State of Antibiotic-Resistant Escherichia coli Cells","authors":"Yu. D. Pakhomov, L. Blinkova, A. M. Abdullaeva, R. K. Valitova","doi":"10.37489/0235-2990-2022-67-9-10-11-17","DOIUrl":"https://doi.org/10.37489/0235-2990-2022-67-9-10-11-17","url":null,"abstract":"Background. It is known that bacteria develop resistance to antibiotics in response to their presence and tend to maintain it for a long time. In addition, microbes can remain viable by passing into an uncultivated state that is not detected by microbiological methods. This state of the population is characterized by cell resistance to various stresses, including the effects of antibiotics.Aim. To study the parameters of transition into an uncultivated state in E.coli M-17 cells resistant to an antibiotic.Material and methods. Resistant E.coli M-17 cells were obtained by culturing the initial population in media with increasing concentrations of ampicillin (up to 50 µg/mL). Seed cultures were prepared from sensitive and resistant substrains, from which the cells were transferred to a hyperosmotic, «starvation» medium — artificial sea water. The resulting populations were incubated for a long time, samples were periodically taken to conduct the assessment of viability parameters.Results. The experiments on long-term incubation of sensitive and resistant populations of E.coli M-17 showed that ampicillin-resistant substrain of the studied culture transitioned into an uncultivated state significantly faster and quantitatively higher than its sensitive variant. The presence of the antibiotic in the inoculum increased the time for the transition of resistant R2 bacteria to a viable uncultivated state to a level of >90% compared to R1. The R1 population at the beginning of the stress exposure massively (up to 77.7%) transitioned into viable but non-culturable cells (VBNCs) in the medium without an antibiotic in a similar seed culture. Periods of cell death were noted during the observation, with those cells becoming a substrate for the living part of the population and could lead to secondary growth of bacteria or partial restoration of dormant cells.Conclusion. Cells resistant to the antibiotic quickly transitioned into the non-culturable state compared to sensitive cells of the studied strain. The addition of an antibiotic to the medium for obtaining a seed culture slowed down the transition of cells to an uncultivated state.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73754267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antiviral Activity of The Preparation Meflokhin® Against COVID-19 Meflokhin®制剂对COVID-19的抗病毒活性研究
Pub Date : 2022-12-28 DOI: 10.37489/0235-2990-2022-67-9-10-49-54
S. Loginova, V. N. Shhukina, S. Savenko, S. Borisevich, K. Filin, I. Berzin, V. Gladkikh
The COVID-19 virus has caused a global emergency and has attracted the attention of healthcare professionals and the public around the world. The significant increase in the number of new cases of infection with this virus demonstrates the relevance of the search for drugs that are effective against this pathogen. The aim of this work was to evaluate the antiviral efficacy of Mefloquin® against COVID-19. The antiviral efficacy of Mefloquin® against the new pandemic virus SARS-CoV-2 was studied in in vitro experiments in Vero C1008 cell culture and in vivo on Syrian golden hamsters. The results of the study revealed that the drug Mefloquine® at a concentration of 2.0 µg ml-1, when applied after infection of cells, suppresses the reproduction of the SARS-CoV-2 virus by 1.7–1.9 lg, the inhibition rate is about 99%. When using Mefloquine, pathological changes in the lung tissue were less pronounced than in the control group. 6 days after infection, it was shown that when using Mefloquine, there was a statistically significant decrease in viral load in the lungs of infected Syrian golden hamsters, with an inhibition rate of 95.5%.
COVID-19病毒已引起全球紧急情况,并引起了世界各地卫生保健专业人员和公众的关注。感染这种病毒的新病例数量的显著增加表明了寻找对这种病原体有效的药物的相关性。本研究的目的是评估美氟喹®对COVID-19的抗病毒疗效。通过Vero C1008细胞体外培养和叙利亚金仓鼠体内实验,研究了Mefloquin®对新型大流行病毒SARS-CoV-2的抗病毒作用。研究结果显示,在感染细胞后应用浓度为2.0µg ml-1的药物甲氟喹®可抑制SARS-CoV-2病毒的繁殖1.7 ~ 1.9 lg,抑制率约为99%。使用甲氟喹时,肺组织的病理改变较对照组明显。感染后6天,结果显示,使用甲氟喹时,感染的叙利亚金仓鼠肺部病毒载量有统计学意义的下降,抑制率为95.5%。
{"title":"Antiviral Activity of The Preparation Meflokhin® Against COVID-19","authors":"S. Loginova, V. N. Shhukina, S. Savenko, S. Borisevich, K. Filin, I. Berzin, V. Gladkikh","doi":"10.37489/0235-2990-2022-67-9-10-49-54","DOIUrl":"https://doi.org/10.37489/0235-2990-2022-67-9-10-49-54","url":null,"abstract":"The COVID-19 virus has caused a global emergency and has attracted the attention of healthcare professionals and the public around the world. The significant increase in the number of new cases of infection with this virus demonstrates the relevance of the search for drugs that are effective against this pathogen. The aim of this work was to evaluate the antiviral efficacy of Mefloquin® against COVID-19. The antiviral efficacy of Mefloquin® against the new pandemic virus SARS-CoV-2 was studied in in vitro experiments in Vero C1008 cell culture and in vivo on Syrian golden hamsters. The results of the study revealed that the drug Mefloquine® at a concentration of 2.0 µg ml-1, when applied after infection of cells, suppresses the reproduction of the SARS-CoV-2 virus by 1.7–1.9 lg, the inhibition rate is about 99%. When using Mefloquine, pathological changes in the lung tissue were less pronounced than in the control group. 6 days after infection, it was shown that when using Mefloquine, there was a statistically significant decrease in viral load in the lungs of infected Syrian golden hamsters, with an inhibition rate of 95.5%.","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":"67 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89142012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Antibiotics and Chemotherapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1